Neil R Cashman

USPTO Granted Patents = 35 (Patent Applications = 23)

CIPO Patents = 6 (Patent Applications = 21)

EPO Patents = 9 (Patent Applications = 19)

Average Co-Inventor Count = 1.9

ph-index = 7

Forward Citations = 129(Granted Patents)

Location History:

Montréal, Québec, CA (2002)
British Columbia, CA (2008)
Saskatoon, CA (2017)
Vancouver, CA (2010 - 2024)

Company Filing History:

16 out of 932

The University of British Columbia

patents

10 out of 10

Amorfix Life Sciences Limited

patents

8 out of 8

Promis Neurosciences Inc.

patents

4. 3 out of 213

University of Saskatchewan

patents

5. 2 out of 291

University Health Network

patents

6. 1 out of 14

Helix Biopharma Corporation

patents

7. 2 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12404321 - Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof (2025-09-02),

2. 12286469 - Humanized antibodies binding to amyloid-beta (A-beta) (2025-04-29),

3. 12173055 - N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto (2024-12-24),

4. 12071472 - Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers (2024-08-27),

5. 11970522 - Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide (2024-04-30),

6. 11905318 - Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide (2024-02-20),

7. 11779629 - Compositions comprising cyclic peptides derived from an A-beta peptide (2023-10-10),

8. 11214613 - Epitopes in the RNA recognition motif 1 (RRM1) of TDP-43 and misfolding-selective antibodies thereto (2022-01-04),

9. 10774120 - Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide (2020-09-15),

10. 10772969 - N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto (2020-09-15),

11. 10759837 - Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide (2020-09-01),

12. 10751382 - Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide (2020-08-25),

13. 10475525 - Methods and systems for predicting misfolded protein epitopes (2019-11-12),

14. 10053510 - FasR antibodies and methods of use (2018-08-21),

15. 9849165 - Oligomer-specific amyloid beta epitope and antibodies (2017-12-26),

Title: The Innovative Journey of Neil R Cashman

Introduction: Neil R Cashman is a renowned inventor based in Vancouver, Canada, known for his groundbreaking contributions to various fields.

Latest Patents: Neil R Cashman holds several patents in the areas of biotechnology, medical devices, and environmental technologies, showcasing his diverse range of expertise.

Career Highlights: With a career spanning over three decades, Neil R Cashman has worked on numerous projects that have revolutionized the industry, earning him a reputation as a visionary in the field of innovation.

Collaborations: Throughout his career, Neil R Cashman has collaborated with leading research institutions, universities, and companies worldwide, fostering a culture of innovation and knowledge sharing.

Conclusion: Neil R Cashman's passion for pushing the boundaries of technology and science continues to inspire the next generation of inventors and innovators globally.

This text is generated by artificial intelligence and may not be accurate.